Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Cost of Revenue: 2021-2025

Historic Cost of Revenue for Tg Therapeutics (TGTX) over the last 3 years, with Sep 2025 value amounting to $28.1 million.

  • Tg Therapeutics' Cost of Revenue rose 200.75% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.0 million, marking a year-over-year increase of 152.01%. This contributed to the annual value of $38.5 million for FY2024, which is 172.35% up from last year.
  • Tg Therapeutics' Cost of Revenue amounted to $28.1 million in Q3 2025, which was up 48.34% from $18.9 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Cost of Revenue peaked at $28.1 million during Q3 2025, and registered a low of $2,000 during Q3 2022.
  • Its 3-year average for Cost of Revenue is $10.5 million, with a median of $8.3 million in 2024.
  • Data for Tg Therapeutics' Cost of Revenue shows a peak YoY skyrocketed of 261,700.00% (in 2023) over the last 5 years.
  • Over the past 5 years, Tg Therapeutics' Cost of Revenue (Quarterly) stood at $139,000 in 2021, then reached $3,000 in 2022, then spiked by 261,700.00% to $7.9 million in 2023, then soared by 96.07% to $15.4 million in 2024, then skyrocketed by 200.75% to $28.1 million in 2025.
  • Its Cost of Revenue was $28.1 million in Q3 2025, compared to $18.9 million in Q2 2025 and $15.5 million in Q1 2025.